Archives of Biomedical Research

Vitamin B12 (cobalamin) is an essential micronutrient involved in DNA synthesis, erythropoiesis, and neurological function. Deficiency can result in hematological, neurological, and psychiatric manifestations, potentially leading to severe and irreversible complications if untreated. This editorial reviews current therapeutic strategies for vitamin B12 deficiency, including conventional supplementation forms, recommended dosages, and treatment durations. 

For decades, psychopharmacology has focused on chemical modulation rather than biological repair. Emerging evidence across cellular, molecular, and systems neuroscience suggests that the adult brain retains dormant capacities for renewal that can be pharmacologically reactivated. Regenerative pharmacology reframes treatment as a process of biological reactivation, reawakening latent plasticity to rebuild damaged circuits rather than merely stabilizing neurotransmission.

Intellectual disability (ID) is a highly heterogeneous neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning. Comprehensive cognitive and adaptive behavior assessments are essential for investigating its underlying causes. While environmental factors contribute, particularly in mild cases, genetic etiologies predominate in moderate to severe forms, accounting for over 50% of these cases. This review explores the complex genomic architecture of ID, including chromosomal abnormalities, monogenic disorders, de novo mutations, polygenic inheritance, and epigenetic dysregulation.

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of refractory hematologic malignancies such as leukemia, lymphoma and multiple myeloma, offering unprecedented remission rates. Yet, complications arising from infections remain a major challenge, particularly in the early post-infusion period and during prolonged immune suppression. This editorial synthesizes recent evidence (2021–2025) on infection epidemiology, risk factors, and stewardship strategies in CAR T-cell recipients.

Will SARS-CoV-2 continue to evolve in such a way that the risk of long COVID may one day become negligible? Theoretically, it's possible, but based on what we've seen so far, it's quite doubtful.
Long COVID is a debilitating and persistent illness that affects people in multiple and dynamic ways. It occurs after a SARS-CoV-2 infection and manifests as a continuous, relapsing-remitting, or progressive disease state affecting one or more organ systems. It can occur after an asymptomatic, mild, or severe SARS-CoV-2 infection.